Document Detail


Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
MedLine Citation:
PMID:  16336449     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Helicobacter pylori eradication was recommended for the prevention of atrophic gastritis in gastroesophageal reflux disease (GERD) patients on long-term omeprazole treatment. It has been also shown that the treatment with proton pump inhibitors produces lower intragastric pH after H. pylori eradication in subjects with peptic ulcer and healthy individuals. The aim of the present study was to test the hypothesis of whether the efficacy of lansoprazole is reduced after the eradication of H. pylori in GERD patients with peptic esophagitis. METHODS: Eight-hour intragastric pH recordings were performed before and after an 8-day course of lansoprazole (30 mg once daily) in 10 H. pylori-positive male patients with reflux esophagitis and were repeated after the H. pylori eradication. Intragastric acidity was measured by using an antimony electrode placed 10 cm below the cardia. RESULTS: Baseline median preprandial, post-prandial, total intragastric pH and the percentage of time with pH < 3 were not different before and after H. pylori eradication without lansoprazole treatment. During lansoprazole treatment, median post-prandial intragastric pH was lower (4 vs 2.7; P < 0.05) and the percentage of time with pH < 3 was longer (3.4%vs 41.8%; P < 0.05) after H. pylori eradication. Median total intragastric pH tended to be lower after eradication but no difference was found in preprandial median pH. CONCLUSIONS: In patients with reflux esophagitis treated with lansoprazole, intragastric pH increased significantly when H. pylori was present, especially in the post-prandial period, whereas baseline pH remained unchanged after H. pylori eradication.
Authors:
Adnan Giral; Cigdem A Celikel; Osman Ozdogan; Nurdan T?z?n; Nefise B Ulusoy; Cem Kalayci
Related Documents :
21941449 - Benefit of intravenous antibiotic therapy in patients referred for treatment of neurolo...
21707189 - Amount of earnings during prize contingency management treatment is associated with pos...
21175539 - Corporate sponsors.
1858969 - Five cases of encephalitis during treatment of loiasis with diethylcarbamazine.
21736509 - Long-term carriage of extended-spectrum beta-lactamase-producing escherichia coli.
8941419 - Efficacy of a novel copper-based footbath preparation for the treatment of ovine footro...
21352989 - Topical application of a biodegradable disc with amiodarone for atrial fibrillation.
23124789 - Time to secondary progression in patients with multiple sclerosis who were treated with...
16131679 - Lower-extremity amputation: a 6-year follow-up study in brazil.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of gastroenterology and hepatology     Volume:  20     ISSN:  0815-9319     ISO Abbreviation:  J. Gastroenterol. Hepatol.     Publication Date:  2005 Dec 
Date Detail:
Created Date:  2005-12-12     Completed Date:  2006-02-28     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8607909     Medline TA:  J Gastroenterol Hepatol     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  1886-91     Citation Subset:  IM    
Copyright Information:
Copyright 2005 Blackwell Publishing Asia Pty Ltd.
Affiliation:
Department of Gastroenterology, University of Marmara School of Medicine, Istanbul, Turkey. adnan.giral@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
2-Pyridinylmethylsulfinylbenzimidazoles
Adult
Anti-Ulcer Agents / therapeutic use*
Gastric Acidity Determination
Gastroesophageal Reflux / drug therapy*,  microbiology*
Gastroscopy
H(+)-K(+)-Exchanging ATPase / antagonists & inhibitors
Helicobacter Infections / drug therapy*
Helicobacter pylori*
Humans
Hydrogen-Ion Concentration
Male
Omeprazole / analogs & derivatives*,  therapeutic use
Proton Pumps / antagonists & inhibitors
Statistics, Nonparametric
Treatment Outcome
Chemical
Reg. No./Substance:
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Anti-Ulcer Agents; 0/Proton Pumps; 103577-45-3/lansoprazole; 73590-58-6/Omeprazole; EC 3.6.1.10/H(+)-K(+)-Exchanging ATPase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical implications of the extent of invasion of T3 esophageal cancer by endoscopic ultrasound.
Next Document:  Expression of retinoid receptors in multiple cell lineages in the gastric mucosae of mice and humans...